140 related articles for article (PubMed ID: 37549660)
1. Complete Remission of a Diffuse Large B-Cell Lymphoma in a Young Patient, with Severe Tuberous Sclerosis, Treated with Metronomic Chemotherapy and Ibrutinib: A Case Report.
Banchi M; Lanzolla T; Di Napoli A; Bandini A; Bocci G; Cox MC
Chemotherapy; 2024; 69(1):40-44. PubMed ID: 37549660
[TBL] [Abstract][Full Text] [Related]
2. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
3. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Tian C; Chen Z; Li Y
J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
[TBL] [Abstract][Full Text] [Related]
4. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
[TBL] [Abstract][Full Text] [Related]
5. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
6. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.
Cox MC; Pelliccia S; Marcheselli L; Battistini R; Arcari A; Borza PA; Patti C; Casaroli I; di Landro F; Di Napoli A; Fabbri F; Caridi M; Tafuri A; Bocci G; Musuraca G
Invest New Drugs; 2019 Jun; 37(3):548-558. PubMed ID: 31028663
[TBL] [Abstract][Full Text] [Related]
7. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.
Wilson WH; Wright GW; Huang DW; Hodkinson B; Balasubramanian S; Fan Y; Vermeulen J; Shreeve M; Staudt LM
Cancer Cell; 2021 Dec; 39(12):1643-1653.e3. PubMed ID: 34739844
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Younes A; Sehn LH; Johnson P; Zinzani PL; Hong X; Zhu J; Patti C; Belada D; Samoilova O; Suh C; Leppä S; Rai S; Turgut M; Jurczak W; Cheung MC; Gurion R; Yeh SP; Lopez-Hernandez A; Dührsen U; Thieblemont C; Chiattone CS; Balasubramanian S; Carey J; Liu G; Shreeve SM; Sun S; Zhuang SH; Vermeulen J; Staudt LM; Wilson W;
J Clin Oncol; 2019 May; 37(15):1285-1295. PubMed ID: 30901302
[TBL] [Abstract][Full Text] [Related]
10. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
11. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Johnson NA; Slack GW; Savage KJ; Connors JM; Ben-Neriah S; Rogic S; Scott DW; Tan KL; Steidl C; Sehn LH; Chan WC; Iqbal J; Meyer PN; Lenz G; Wright G; Rimsza LM; Valentino C; Brunhoeber P; Grogan TM; Braziel RM; Cook JR; Tubbs RR; Weisenburger DD; Campo E; Rosenwald A; Ott G; Delabie J; Holcroft C; Jaffe ES; Staudt LM; Gascoyne RD
J Clin Oncol; 2012 Oct; 30(28):3452-9. PubMed ID: 22851565
[TBL] [Abstract][Full Text] [Related]
12. A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy.
Kim KM; Yoon DH; Lee SG; Lim SN; Sug LJ; Huh J; Suh C
J Korean Med Sci; 2009 Jun; 24(3):525-8. PubMed ID: 19543522
[TBL] [Abstract][Full Text] [Related]
13. BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma.
Palickova M; Mocikova H; Vernerova Z; Campr V; Kozak T
Leuk Lymphoma; 2013 Sep; 54(9):2081-2. PubMed ID: 23311295
[No Abstract] [Full Text] [Related]
14. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
[TBL] [Abstract][Full Text] [Related]
15. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
16. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
17. CD56-positive diffuse large B-cell lymphoma/leukemia with
Liu Y; Shen J; Awal Issah M; Liu T; Zhou H; Fu H
J Int Med Res; 2020 May; 48(5):300060520918087. PubMed ID: 32363958
[TBL] [Abstract][Full Text] [Related]
18. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
Xia Y; Zhang X
Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
[TBL] [Abstract][Full Text] [Related]
20. Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
Balasubramanian S; Wang S; Major C; Hodkinson B; Schaffer M; Sehn LH; Johnson P; Zinzani PL; Carey J; Shreeve SM; Sun S; Gerecitano J; Vermeulen J; Staudt LM; Wilson W
Br J Haematol; 2021 Jul; 194(1):83-91. PubMed ID: 33942292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
